Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
CSE: AIML
OTCQB: AIMLF
FWB: 42FB
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
Read more in Archive
May 11, 2026
AIML Appoints Dr. Martin Green to Medical Advisory Board and Issue Options
Read More
March 31, 2026
Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform
Read More
March 27, 2026
AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000
Read More
March 25, 2026
AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis
Read More
March 12, 2026
AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures
Read More
February 24, 2026
Neural Cloud Enters Distribution Agreement with Intelimed to Expand into Latin America
Read More
Full Recording of 2025 Shareholder Update
AIML’s 2025 Shareholder Update from CEO & Executive Chairman, Paul Duffy, outlining key milestones from 2025 - including Product Development, Commercial Traction, and Regulatory Progress - along with the roadmap for 2026. The livestream concludes with a Q&A with the live audience.
Visit pageCorporate Governance
Board of Directors
Financials
Read more on CSE
Read more
AGM Materials
Charters & Policies
Company Structure
253.9
Million
Shares Outstanding
16
Million
Options
190.7
Million
Warrants Outstanding
460.6
Million
Fully Diluted